Abstract:Antibiotic-resistant bacteria represent a serious threat to modern medicine and human life. Only a minority of antibacterial agents are active against Gram-negative bacteria. Hence, the development of novel antimicrobial agents will always be a vital need. In an effort to discover new therapeutics against Gram-negative bacteria, we previously reported a structure-activity-relationship (SAR) study on 1,2-disubstituted benzimidazole derivatives. Compound III showed a potent activity against tolC-mutant Escherichia coli with an MIC value of 2 μg/mL, representing a promising lead for further optimization. Building upon this study, herein, 49 novel benzimidazole compounds were synthesized to investigate their antibacterial activity against Gram-negative bacteria. Our design focused on three main goals, to address the low permeability of our compounds and improve their cellular accumulation, to expand the SAR study to the unexplored ring C, and to optimize the lead compound (III) by modification of the methanesulfonamide moiety. Compounds (25a-d, 25f-h, 25k, 25l, 25p, 25r, 25s, and 26b) exhibited potent activity against tolC-mutant E. coli with MIC values ranging from 0.125 to 4 μg/mL, with compound 25d displaying the highest potency among the tested compounds with an MIC value of 0.125 μg/mL. As its predecessor, III, compound 25d exhibited an excellent safety profile without any significant cytotoxicity to mammalian cells. Time-kill kinetics assay indicated that 25d exhibited a bacteriostatic activity and significantly reduced E. coli JW55031 burden as compared to DMSO. Additionally, combination of 25d with colistin partially restored its antibacterial activity against Gram-negative bacterial strains (MIC values ranging from 4 to 16 μg/mL against E. coli BW25113, K. pneumoniae, A. baumannii, and P. aeruginosa). Furthermore, formulation of III and 25d as lipidic nanoparticles (nanocapsules) resulted in moderate enhancement of their antibacterial activity against Gram-negative bacterial strains (A. Baumannii, N. gonorrhoeae) and compound 25d demonstrated superior activity to the lead compound III. These findings establish compound 25d as a promising candidate for treatment of Gram-negative bacterial infections and emphasize the potential of nano-formulations in overcoming poor cellular accumulation in Gram-negative bacteria where further optimization and investigation are warranted to improve the potency and broaden the spectrum of our compounds.

Design, Synthesis and Antimicrobial Evaluation of Novel Benzimidazoleincorporated Naphthalimide Derivatives As Salmonella Typhimurium DNA Intercalators, and Combination Researches.

Design, synthesis, and biological evaluation of novel carbazole aminothiazoles as potential DNA-targeting antimicrobial agents

Novel Potentially Antibacterial Naphthalimide-Derived Metronidazoles: Design, Synthesis, Biological Evaluation and Supramolecular Interactions with DNA, Human Serum Albumin and Topoisomerase II

Novel Naphthalimide Nitroimidazoles As Multitargeting Antibacterial Agents Against Resistant Acinetobacter Baumannii.

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Novel Aminopyrimidinyl Benzimidazoles As Potentially Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Discovery of Natural Berberine-Derived Nitroimidazoles As Potentially Multi-Targeting Agents Against Drug-Resistant Escherichia Coli

Design, Synthesis and Antimicrobial Evaluation of Novel Benzimidazole-Incorporated Sulfonamide Analogues

Unique Aminothiazolyl Coumarins As Potential DNA and Membrane Disruptors Towards Enterococcus Faecalis

Design and Synthesis of Quinazolinone Imidazoles and Their Antibacterial and DNA-targeting Investigation

Design, Synthesis, and Biological Evaluation of Novel Benzimidazole Derivatives and Their Interaction with Calf Thymus DNA and Synergistic Effects with Clinical Drugs

Design, synthesis and biological evaluation of berberine-benzimidazole hybrids as new type of potentially DNA-targeting antimicrobial agents.

Design, Synthesis, and Antimicrobial Evaluation of Novel Quinolone Imidazoles and Interactions with MRSA DNA

Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole.

Novel Naphthalimide Aminothiazoles As Potential Multitargeting Antimicrobial Agents

Synthesis and Antimicrobial Evaluation of (Z)-5-((3-phenyl-1h-pyrazol-4- Yl)methylene)-2-thioxothiazolidin-4-one Derivatives

Synthesis and Bioactive Evaluations of Novel Benzotriazole Compounds As Potential Antimicrobial Agents and the Interaction with Calf Thymus DNA

A Series of Naphthalimide Azoles: Design, Synthesis and Bioactive Evaluation As Potential Antimicrobial Agents

1,2,3-Triazole-Derived Naphthalimides As A Novel Type Of Potential Antimicrobial Agents: Synthesis, Antimicrobial Activity, Interaction With Calf Thymus Dna And Human Serum Albumin

SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria

Novel Benzimidazole Derived Naphthalimide Triazoles: Synthesis, Antimicrobial Activity and Interactions with Calf Thymus DNA